thor-707
Recombinant proteinexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 20, 2019 (NCT04009681)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2
- Hodgkin Disease · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Stomach Neoplasms · Phase 2
Mechanism of action
- Interleukin-2Supplementation
IL2 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05179603 | Phase 2 | Dec 7, 2021 | Merck, Sanofi |
| NCT05104567 | Phase 2 | Nov 30, 2021 | Merck, Sanofi |
| NCT04913220 | Phase 1/Phase 2 (Phase 2) | Jul 15, 2021 | Sanofi |
| NCT04009681 | Phase 1/Phase 2 (Phase 2) | Jun 20, 2019 | Synthorx, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 3 | 3 | 1 | 2021 |
| Merck | For profit | 2 | 0 | 1 | 2021 |
| Synthorx, Inc. | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1